Close Menu

SAN FRANCISCO (GenomeWeb) – Illumina today announced the launch of three new sequencing systems and provided an update on its diagnostic plans in the noninvasive prenatal testing and oncology markets.

Speaking at the JP Morgan Healthcare Conference, CEO Jay Flatley preannounced fourth quarter revenues of $512 million, as well as $1.86 billion in FY 2014 revenues, representing 31 percent year-over-year growth. He said the firm expects revenue growth of 20 percent in FY 2015.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The head of Operation Warp Speed tells Bloomberg he expects the paused AstraZeneca and Johnson & Johnson vaccine trials to resume soon.

A new UK government says socioeconomic factors, not genetics, account for disparities in deaths due to COVID-19 between ethnic groups, the Financial Times reports.

NPR reports on an Alzheimer's disease drug trial that is continuing despite the pandemic.

In Nature this week: CRISPR-Cas3 system for making large deletions efficiently, more.